ARTICLE | Emerging Company Profile
Histogen: Regenerating tissue science
May 5, 2008 7:00 AM UTC
Despite having approved products, many of the first wave of tissue regeneration companies were unable to surmount manufacturing and reimbursement obstacles to become sustainable businesses. Histogen Inc. thinks it has solved both sets of problems with a new business model and a new take on technology for expanding fibroblasts from newborns. Last week, the company announced the initial close of its series A round at $5.4 million.
Histogen CEO Gail Naughton cofounded Advanced Tissue Sciences Inc., which marketed Dermagraft human fibroblast-derived dermal substitute for diabetic foot ulcers but filed for Chapter 11 in late 2002...